CN100335461C - 芳基磺酰基苯胺脲 - Google Patents

芳基磺酰基苯胺脲 Download PDF

Info

Publication number
CN100335461C
CN100335461C CNB99811233XA CN99811233A CN100335461C CN 100335461 C CN100335461 C CN 100335461C CN B99811233X A CNB99811233X A CN B99811233XA CN 99811233 A CN99811233 A CN 99811233A CN 100335461 C CN100335461 C CN 100335461C
Authority
CN
China
Prior art keywords
alkyl
hydrogen
compound
assorted
assorted alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB99811233XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1319088A (zh
Inventor
乔纳森·B·豪兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Roa Kwesi Shane Co
Amgen SF LLC
Amgen Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of CN1319088A publication Critical patent/CN1319088A/zh
Application granted granted Critical
Publication of CN100335461C publication Critical patent/CN100335461C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CNB99811233XA 1998-09-23 1999-09-21 芳基磺酰基苯胺脲 Expired - Fee Related CN100335461C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10088898P 1998-09-23 1998-09-23
US60/100,888 1998-09-23

Publications (2)

Publication Number Publication Date
CN1319088A CN1319088A (zh) 2001-10-24
CN100335461C true CN100335461C (zh) 2007-09-05

Family

ID=22282047

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB99811233XA Expired - Fee Related CN100335461C (zh) 1998-09-23 1999-09-21 芳基磺酰基苯胺脲

Country Status (23)

Country Link
US (3) US6214880B1 (enExample)
EP (1) EP1115701B1 (enExample)
JP (1) JP3926983B2 (enExample)
KR (1) KR100642184B1 (enExample)
CN (1) CN100335461C (enExample)
AT (1) ATE240940T1 (enExample)
AU (1) AU747663B2 (enExample)
BR (1) BR9913903A (enExample)
CA (1) CA2343204C (enExample)
CZ (1) CZ2001934A3 (enExample)
DE (1) DE69908156T2 (enExample)
DK (1) DK1115701T3 (enExample)
EA (1) EA003924B1 (enExample)
ES (1) ES2194547T3 (enExample)
HU (1) HUP0103884A3 (enExample)
IL (2) IL142066A0 (enExample)
NO (1) NO20011453L (enExample)
NZ (1) NZ510435A (enExample)
PL (1) PL198394B1 (enExample)
PT (1) PT1115701E (enExample)
SK (1) SK284757B6 (enExample)
WO (1) WO2000017159A1 (enExample)
ZA (1) ZA200102033B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797429A (zh) * 2012-11-21 2015-07-22 日本曹达株式会社 使用了非酚类化合物的记录材料

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508644D0 (en) * 1995-04-28 1995-06-14 Exxon Chemical Patents Inc Fuel compositions
BR9913903A (pt) * 1998-09-23 2001-07-03 Tularik Inc Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6355628B1 (en) * 1999-07-29 2002-03-12 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides
AR031098A1 (es) * 2000-03-16 2003-09-10 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
US6664259B2 (en) 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (es) 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
WO2002020463A2 (en) * 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US6822001B2 (en) 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100850330B1 (ko) 2001-02-28 2008-08-04 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Ｎ-(아릴)-2-아릴에텐술폰아미드 및 이를 이용한 약학적 조성물
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
JP4434744B2 (ja) * 2002-01-30 2010-03-17 アムジェン インコーポレイテッド アリールスルホンアミドベンジル化合物
WO2003063796A2 (en) * 2002-01-30 2003-08-07 Tularik Inc. Heterocyclic arylsulfonamidobenzylic compounds
EP1534284B1 (en) 2002-02-28 2011-07-27 Temple University - Of The Commonwealth System of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
MXPA06001566A (es) * 2003-08-12 2006-05-15 Amgen Inc Compuestos arilsulfonamidobencilicos.
US20050124664A1 (en) * 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050154455A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
US20060062822A1 (en) * 2004-09-21 2006-03-23 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20070027530A1 (en) * 2005-07-26 2007-02-01 Medtronic Vascular, Inc. Intraluminal device, catheter assembly, and method of use thereof
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070067020A1 (en) * 2005-09-22 2007-03-22 Medtronic Vasular, Inc. Intraluminal stent, delivery system, and a method of treating a vascular condition
BRPI0710559A2 (pt) * 2006-04-21 2011-08-16 Smithkline Beecham Corp antagonistas de receptores de il-8
DK2009992T3 (da) * 2006-04-21 2012-08-13 Glaxosmithkline Llc Il-8 receptor-antagonister
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
AR061571A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
KR20100096101A (ko) * 2007-10-19 2010-09-01 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 박테리아 독성을 억제하는 방법 및 이에 대한 화합물
EP2385831A4 (en) * 2009-01-09 2014-03-26 Uab Research Foundation SMALL MOLECULAR HEMMER OF NADS, NAMNAT AND NMNAT
US9444712B2 (en) 2012-11-21 2016-09-13 Cisco Technology, Inc. Bandwidth on-demand services in multiple layer networks
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2456731A1 (fr) * 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
EP0472053A2 (en) * 1990-08-20 1992-02-26 Eisai Co., Ltd. Sulfonamide derivatives
WO1997030677A2 (en) * 1996-02-22 1997-08-28 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1955207A (en) 1931-09-16 1934-04-17 Ig Farbenindustrie Ag Mothproofing agent
DE622494C (de) 1932-01-03 1935-11-29 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Mono- bzw. Polynitropolysulfonen und deren Reduktionsprodukten
US2358365A (en) 1940-08-03 1944-09-19 Parke Davis & Co Sulphonamide derivatives and process for obtaining the same
US2402623A (en) 1943-06-24 1946-06-25 Rohm & Haas Nu-nitroaryl haloarylsulphonamides
CH361275A (de) 1957-09-10 1962-04-15 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
GB938890A (en) 1961-02-03 1963-10-09 Boots Pure Drug Co Ltd New fungicidal compositions and compounds
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
GB1242057A (en) 1968-07-04 1971-08-11 Ici Ltd Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (nl) 1970-04-13 1984-07-16 Minnesota Mining & Mfg Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking.
DE3623184A1 (de) 1986-07-10 1988-01-14 Kali Chemie Ag Verfahren zur herstellung von n-fluorsulfonamiden
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
FR2645537B1 (fr) 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5189211A (en) 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AU1208999A (en) 1997-11-10 1999-05-31 Array Biopharma, Inc. Compounds which inhibit tryptase activity
AU1529799A (en) 1997-12-23 1999-07-12 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
BR9913903A (pt) * 1998-09-23 2001-07-03 Tularik Inc Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica
US6355628B1 (en) * 1999-07-29 2002-03-12 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2456731A1 (fr) * 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
EP0472053A2 (en) * 1990-08-20 1992-02-26 Eisai Co., Ltd. Sulfonamide derivatives
WO1997030677A2 (en) * 1996-02-22 1997-08-28 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797429A (zh) * 2012-11-21 2015-07-22 日本曹达株式会社 使用了非酚类化合物的记录材料

Also Published As

Publication number Publication date
PL346797A1 (en) 2002-02-25
NO20011453L (no) 2001-05-23
IL142066A (en) 2006-07-05
AU747663B2 (en) 2002-05-16
NO20011453D0 (no) 2001-03-22
US7060718B2 (en) 2006-06-13
WO2000017159A1 (en) 2000-03-30
NZ510435A (en) 2003-04-29
IL142066A0 (en) 2002-03-10
DE69908156T2 (de) 2003-12-24
HUP0103884A3 (en) 2002-11-28
ZA200102033B (en) 2001-09-12
EA200100376A1 (ru) 2001-08-27
DE69908156D1 (de) 2003-06-26
CA2343204C (en) 2008-04-29
KR20010079892A (ko) 2001-08-22
SK4002001A3 (en) 2001-09-11
HK1038913A1 (en) 2002-04-04
US6583165B2 (en) 2003-06-24
BR9913903A (pt) 2001-07-03
CZ2001934A3 (cs) 2001-08-15
EA003924B1 (ru) 2003-10-30
AU6058099A (en) 2000-04-10
KR100642184B1 (ko) 2006-11-10
ATE240940T1 (de) 2003-06-15
JP2002526472A (ja) 2002-08-20
PL198394B1 (pl) 2008-06-30
CA2343204A1 (en) 2000-03-30
HUP0103884A2 (hu) 2002-05-29
CN1319088A (zh) 2001-10-24
US20010027211A1 (en) 2001-10-04
PT1115701E (pt) 2003-09-30
US6214880B1 (en) 2001-04-10
SK284757B6 (sk) 2005-11-03
EP1115701B1 (en) 2003-05-21
JP3926983B2 (ja) 2007-06-06
EP1115701A1 (en) 2001-07-18
US20030207864A1 (en) 2003-11-06
DK1115701T3 (da) 2003-06-23
ES2194547T3 (es) 2003-11-16

Similar Documents

Publication Publication Date Title
CN100335461C (zh) 芳基磺酰基苯胺脲
CN108314663B (zh) 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
EP1318978B1 (en) N-acylsulfonamide apoptosis promoters
JP4084189B2 (ja) 尿素の新誘導体、それらの製造方法、それらの薬剤としての使用、製薬組成物及び新規な用途
CZ20013248A3 (cs) Nové sloučeniny a prostředky jako inhibitory proteázy
CN1649582A (zh) 氨基－甲基取代的四环素类化合物
EA005210B1 (ru) Сульфонамиды гидроксидифенилмочевины в качестве антагонистов рецептора ил-8
JP2013537535A (ja) Ｓｔａｔタンパク質の阻害剤としての、置換２−ヒドロキシ−４−（２−（フェニルスルホンアミド）アセトアミド）安息香酸類似体
CZ159098A3 (cs) Inhibitory metaloproteinázy a farmaceutický prostředek
JP2011500734A (ja) 新規なヒストンデアセチラーゼインヒビター、その調製方法および使用
WO2013006734A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
KR20210044802A (ko) 1-메틸-4-[(4-페닐페닐)설포닐메틸]사이클로헥시아놀 및 1-메틸-4-[[4-(2-피리딜)페닐]설포닐메틸]사이클로헥사놀 화합물 및 이의 치료학적 용도
RU2382029C2 (ru) Новые производные циклогексана
EP3628664A1 (en) Irreversible inhibitors of kras g12c mutant
CN105228609A (zh) 新的转录因子调节剂
JPH10195037A (ja) フェノール誘導体
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
CN109796418B (zh) 含有4-苯基-1,2,3-三氮唑的苯丙氨酸衍生物及其制备方法与应用
EP1285911A2 (en) Arylsulfonanilide ureas
HK1038913B (en) Arylsulfonanilide ureas
MXPA01002717A (es) Ureas de arilsulfonanilida
JP2013249257A (ja) グリシントランスポーター阻害物質

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: AMGEN CO., LTD.

Free format text: FORMER OWNER: EMINGEN SF CO.,LTD.

Effective date: 20081010

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: AROAQURSIC CO., LTD.

Free format text: FORMER NAME OR ADDRESS: FIGURE LARIC CO.,LTD.

Owner name: EMINGEN SF CO.,LTD.

Free format text: FORMER NAME OR ADDRESS: AROAQURSIC CO., LTD.

CP03 Change of name, title or address

Address after: California, USA

Patentee after: A Roa Kwesi Shane Co.

Address before: California, USA

Patentee before: Tularik Inc.

Address after: California, USA

Patentee after: Amgen company SF

Address before: California, USA

Patentee before: A Roa Kwesi Shane Co.

TR01 Transfer of patent right

Effective date of registration: 20081010

Address after: California, USA

Patentee after: Amgen Limited by Share Ltd.

Address before: California, USA

Patentee before: Amgen company SF

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070905

Termination date: 20091021